Evercore ISI analyst Mark Lipacis raised the firm’s price target on Marvell (MRVL) to $155 from $133 and keeps an Outperform rating on the shares following a January quarter beat and “healthy raise” that was consistent with the firm’s checks and preview.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRVL:
- Morning Movers: Nutex Health sinks after fourth quarter results
- Marvell price target raised to $135 from $130 at B. Riley
- Marvell price target raised to $115 from $105 at RBC Capital
- Invesco QQQ Trust ETF (QQQ) Daily Update, 3/6/2026
- Marvell Technology: Accelerating AI Data Center Momentum and Long-Term Growth Upside Supports Buy Rating